Semaglutide 0.25mg: the starting dose explained

Step one: why semaglutide treatment doesn't start at the dose that works

Starting any GLP-1 medicine at its full maintenance strength would, for most people, mean a sharp onset of nausea, vomiting or stomach cramping. The 0.25mg semaglutide starting dose sidesteps that by giving the gut time to adapt to slowed gastric emptying before the medicine is doing its maximum metabolic work. Think of it less as a treatment dose and more as an introduction between your digestive system and a new way of processing meals.

After four weeks at 0.25mg, the standard pathway moves to 0.5mg, then 1mg, a dose covered in its own guide for those who want to understand what that step involves, then 1.7mg, and finally the 2.4mg maintenance dose. Each rung of that ladder is held for roughly four weeks, though your prescriber may recommend staying longer at any point if your body needs more time. The pace is clinical, not rigid. Patients who have found the full Wegovy dose schedule useful often say they wished they'd understood the starting step before they began, because the first month can feel underwhelming from a weight-loss perspective while being entirely on track.

It is worth noting that the 2.4mg maintenance dose is no longer the ceiling: the MHRA approved a 7.2mg semaglutide dose in early 2026 for eligible adults, available as a dedicated single-dose pen. That higher step is a long way from where 0.25 semaglutide sits, but knowing the runway exists can make the starting point feel less arbitrary.

What to expect during the first four weeks on 0.25mg semaglutide

Side effects at this dose are usually mild. Nausea is the most commonly reported, and it tends to settle within the first week or two as the body adjusts. Other symptoms, including loose stools, mild indigestion or a sense of fullness after smaller meals, follow a similar pattern: more noticeable in week one, fading by week three or four for most people.

A question our prescribers hear most weeks is whether the side effects at 0.25mg are a sign that the dose is already too high. Almost always, they are not; they are the expected response to starting the medicine. Stopping early or skipping ahead to see if a higher dose works faster are both likely to make the experience harder, not easier. If symptoms feel severe or are not settling, that is a conversation to have with your prescriber, not a reason to change the dose without guidance.

Practically, the 0.25mg pen is injected once a week into the abdomen, thigh, or upper arm, rotating sites. The pen is stored in the fridge between doses. For full detail on storage windows and injection guidance, the medicine's Patient Information Leaflet is the authoritative reference. Our frequently asked questions page covers some of the practical questions that come up most often at this stage.

Who begins on the 0.25mg semaglutide starting dose

Every adult starting Wegovy for weight management begins at 0.25mg, regardless of their starting weight, BMI or how much weight they hope to lose. The starting dose is not calibrated to your individual needs; it is a universal first step built into the licensed schedule. Semaglutide is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition such as high blood pressure, high cholesterol, or pre-diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

Eligibility is assessed by a prescriber at consultation, not by BMI alone. A full picture of your health history, current medicines, and any contraindications shapes the decision. If you are considering the Wegovy treatment route privately, the process at a regulated pharmacy begins with a clinical consultation, and nothing is dispensed before that assessment is complete.

People transferring from another provider who are already established on a higher dose would not return to 0.25mg unless clinically indicated; their prescriber reviews the evidence of their current treatment and dose before deciding the appropriate starting point with a new service. The semaglutide dosing overview covers the full picture for those at other points in their journey.

The cost context for the starting dose

From a cost perspective, the 0.25mg pen and the 0.5mg pen are typically priced the same as each other in the private market, even though the therapeutic effect at 0.25mg is primarily about tolerability rather than weight loss. Each pre-filled Wegovy pen covers four weekly doses at a single strength. As the dose increases, so does the list price of each pen, which is why what Wegovy costs per month varies significantly depending on where in the schedule you are.

Eli Lilly revised Mounjaro's UK list pricing from September 2025, and the wider private market for weight-loss injections has shifted accordingly. For semaglutide, reported private prices vary by dose and provider. Any legitimate price should include the clinical consultation, the prescription itself, and dispensing; a price that appears to cover only the pen is likely excluding fees that will surface later. At nume, one price covers everything: free consultation, prescription, and free next-working-day delivery, with clinical review before every repeat. No subscription, no hidden extras.

For a broader look at how semaglutide sits alongside tirzepatide and other licensed options, the weight-loss treatment overview is a useful next step. And if you want to understand what comes after the 0.25mg phase, semaglutide 0.5mg is covered in detail separately.